Enteral nutrition during the treatment of head and neck carcinoma -: Is a percutaneous endoscopic gastrostomy tube preferable to a nasogastric tube?

被引:0
|
作者
Mekhail, TM
Adelstein, DJ
Rybicki, LA
Larto, MA
Saxton, JP
Lavertu, P
机构
[1] Cleveland Clin Fdn, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Dept Radiat Therapy, Cleveland, OH 44195 USA
[4] Univ Hosp Cleveland, Dept Otolaryngol Head & Neck Surg, Cleveland, OH 44106 USA
关键词
nasogastric tube; percutaneous gastrostomy; enteral feeding; head and neck carcinoma;
D O I
10.1002/1097-0142(20010501)91:9<1785::AID-CNCR1197>3.0.CO;2-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Multimodality treatments for patients with squamous cell head and neck carcinoma often produce significant mucositis and dysphagia, mandating enteral nutritional support. Patient preference has resulted in the increasing use of percutaneous endoscopic gastrostomy (PEG) tubes rather than nasogastric (NG) tubes. Anecdotal observations of prolonged PEG dependence and of a need for pharyngoesophageal dilatation in PEG patients prompted a retrospective review of the use of both types of feeding tubes. METHODS. Patients who were treated on clinical trials of radiotherapy or chemoradiotherapy for squamous cell head and neck carcinoma between 1989 and 1997 were reviewed retrospectively. Data were gathered regarding demographics, primary tumor site, T and N classifications, and the need for feeding tube placement. In patients requiring feeding tubes, the type and duration of the feeding tube, the need for tracheostomy, the need for pharyngoesophageal dilatation, and the degree of mucositis and dysphagia at baseline and at 1 month, 3 months, 6 months, and 12 months after beginning treatment were recorded. Comparisons were then made between the NG and the PEG groups. RESULTS. Ninety-one feeding tubes were placed in 158 patients over the 8-year interval. A hypopharyngeal primary site, female gender, a T4 primary tumor, and treatment with chemoradiotherapy were predictive of a need for feeding tube placement. NG tubes were placed in 29 patients, and PEG tubes were placed in 62 patients. PEG patients had more dysphagia at 3 months (59% vs. 30%, respectively; P = 0.015) and at 6 months (30% vs. 8%, respectively; P = 0.029) than NG patients. The median tube duration was 28 weeks for PEG patients compared with 8 weeks for NG patients, (P < 0.001). Twenty-three percent of PEG patients needed pharyngoesophageal dilatation compared with 4% of NG patients (P = 0.022). These end points could not be correlated with age, stage, primary tumor site, or tracheostomy placement. CONCLUSIONS. Although patients treated for head and neck carcinoma find that the PEG tube is a more acceptable route for enteral nutrition than the NG tube, in the authors' experience, a PEG tube was required for longer periods of time and was associated with more persistent dysphagia and an increased need for pharyngoesophageal dilatation. A randomized prospective trial is needed to test these observations. (C) 2001 American Cancer Society.
引用
收藏
页码:1785 / 1790
页数:6
相关论文
共 50 条
  • [31] Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances
    Gomes, Claudio A. R., Jr.
    Silva Lustosa, Suzana Angelica
    Matos, Delcio
    Andriolo, Regis B.
    Waisberg, Daniel R.
    Waisberg, Jaques
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (11):
  • [32] Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances
    Gomes, Claudio A. R., Jr.
    Andriolo, Regis B.
    Bennett, Cathy
    Lustosa, Suzana A. S.
    Matos, Delcio
    Waisberg, Daniel R.
    Waisberg, Jaques
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05):
  • [33] Safety of Percutaneous Endoscopic Gastrostomy (PEG) Tube for Enteral Nutrition in Patients with Amyotrophic Lateral Sclerosis (ALS)
    Salami, Augustine
    Schiesser, Rachel
    Ditah, Ivo
    Newman, Daniel
    Alaradi, Osama
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S522 - S522
  • [34] Changes in Gastroesophageal Reflux in Patients With Nasogastric Tube Followed by Percutaneous Endoscopic Gastrostomy
    Lee, Tzong-Hsi
    Shiun, Yu-Chien
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2011, 110 (02) : 115 - 119
  • [35] Endoscopic treatment of transcolonic misplacement of a percutaneous endoscopic gastrostomy tube
    von Delius, S.
    Huber, W.
    Dienemann, T.
    Gaa, J.
    Frandah, M.
    Schmid, R. M.
    Meining, A.
    ENDOSCOPY, 2010, 42 : E50 - E51
  • [36] Gastrostomy versus nasogastric tube feeding for chemoradiation patients with head and neck cancer: the TUBE pilot RCT
    Paleri, Vinidh
    Patterson, Joanne
    Rousseau, Nikki
    Moloney, Eoin
    Craig, Dawn
    Tzelis, Dimitrios
    Wilkinson, Nina
    Franks, Jeremy
    Hynes, Ann Marie
    Heaven, Ben
    Hamilton, David
    Guerrero-Urbano, Teresa
    Donnelly, Rachael
    Barclay, Stewart
    Rapley, Tim
    Stocken, Deborah
    HEALTH TECHNOLOGY ASSESSMENT, 2018, 22 (16) : 1 - +
  • [37] The Experience of Head and Neck Cancer Patients With a Percutaneous Endoscopic Gastrostomy Tube at a Canadian Cancer Center
    Osborne, Joanna B.
    Collin, Laura A.
    Posluns, Elaine C.
    Stokes, Edith J.
    Vandenbussche, Katherine A.
    NUTRITION IN CLINICAL PRACTICE, 2012, 27 (05) : 661 - 668
  • [38] STOMAL SEEDING OF HEAD AND NECK-CANCER BY PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE - REPLY
    RUSH, BF
    LEE, DS
    MOHITTABATABAI, MA
    ANNALS OF SURGICAL ONCOLOGY, 1995, 2 (05) : 463 - 463
  • [39] Percutaneous endoscopic gastrostomy versus nasogastric tube feeding during neurorehabilitation. Ifs, ands, or buts
    Qureshi, Ahmad Z.
    Jenkins, Randolph M.
    Thornhill, Tina H.
    NEUROSCIENCES, 2016, 21 (01) : 69 - 71
  • [40] Percutaneous Endoscopic Gastrostomy Tube Is a Negative Prognostic Factor for Recurrent/Metastatic Head and Neck Cancer
    Siano, Marco
    Jarisch, Nadine
    Joerger, Markus
    Espeli, Vittoria
    ANTICANCER RESEARCH, 2018, 38 (06) : 3725 - 3729